Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Yet that "toxic" financing has advanced the science,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 311
Posts 39,480
Boards Moderated 36
Alias Born 09/20/01
160x600 placeholder
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical... GlobeNewswire Inc. - 7/31/2019 7:00:00 AM
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for... GlobeNewswire Inc. - 7/29/2019 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Respo... GlobeNewswire Inc. - 7/17/2019 11:45:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/16/2019 6:01:11 AM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
XenaLives Member Level  Monday, 10/21/19 08:05:57 PM
Re: Grim Reaper post# 215561
Post # of 219849 
Yet that "toxic" financing has advanced the science, left the company without debt, and diluted stockholders less than the customary institutional financed funding devices.

Apparently that 2016 author was wrong and full of sour grapes:

"Unfortunately, these types of exciting speculative investments have burned me in the past. "

The author is a self styled investment guru - I believe this comment on his credibility is pretty accurate:


Comments307 | + Follow
Pump and Dump? Let's look at some of the Author's "hype". Last year, her urged his followers to "dump" ACAD as it had been taken to the "wood shed" and was way over priced. That was at $30/share and he disclosed he owned "Puts". Two months later, ACAD was close to $60. Great call! Or how about EYES, his "long" recommendation (and position) back in last May at around $9 or $10, convincing everyone it was going to $30. It's sitting at under $6 today, right? Another great miscalculation.
A couple other year ago "authoritative" predictions with positions from last March and May disclosures: Ya gotta love his "long" position and recommendations for CAPN at $6/shr with a knowledgable insight that it shoud be worth $10 to $20 shr by now, a year later. It's selling for $1.24. Or, how about hos long position and great recommendations for BIAD at 25 cents/sh. It's selling at around 3 cents, today.
I only read a half dozen or so of your posts available from Seeking Alpha. I had to stop, I was laughing so hard! What stood out, however, that in each of the articles I did view, you seemed totally focused on using this venue to slam or promote a stock in which you ALWAYS held. the other outstanding conclusion I drew, was that you were ALWAYS consistently WRONG in your projecctions and price predictions.
I guess there is something to be said for being consistent. It's very much like my experience in picking winners at the horse track. I'd spend hours reading tips and racing forms, but when it was all said and done, my wife asked me who I picked, and she bet against me- usually winning.
From reading your Bio, it appears you're still looking for a job. I don't think you'll get any offers based upon your stock-picking recommendation successes. I'd encourage you to rethink your messaging. Offer facts without a corresponding equity interest based on some original research, not other writer's promotional pieces already in publication. Offering self-serving, biased information is a waste of ink and offers little in the way of job appeal!

27 Apr 2016, 02:00 PM


I'll stick with the science:


IP Protection:09/29/19

GUT and BRAIN - barrier and permeability 09/29/19

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist